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Abstract
Opioid addiction has been on the rise since 1990, when physicians began administering
prescription pain medications. The population has undergone a drastic change from opioid
prescriptions such as oxycodone to illicit forms, such as heroin, to aid pain management. Illegal
opiates became the alternative drug at a lower cost to fulfill cravings and dependence that
prescriptions may no longer feed. With a rise in dependence, pharmaceutical laboratories
developed medicated assistant treatments (MAT) to aid in this crisis, more formally known as
buprenorphine and methadone. Studies conducted show evidence of a decrease in illicit opioid
use when using these medicated treatments and can lead to successful retention of the addiction.
The users' experiences are often overlooked in terms of how administration occurs and when the
taper of these therapies begins. Anecdotal findings suggest that prescribers continue to prescribe
medications with intended harm reduction approaches instead of focusing on abstinence. This
study focuses on the history of opioid prescription, addiction, and medical information regarding
medication therapy, harm reduction, and the deliverance of why persons administered MAT has
been prescribed for an extended amount of time. This study focuses on who is primarily
responsible for the length of MAT treatment. Interviews with persons previously or currently
prescribed medication-assisted treatment will initiate personal experiences to conclude whether
the client or physician controls MAT administration length. Recommendations of participants
will be discussed regarding their opinions on the length of treatment.
Keywords: opioid(s), buprenorphine, methadone, medicated assisted treatment, length of
treatment, harm reduction, counseling.
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Chapter I: Statement of Problem
Opioid addiction is an epidemic that primarily affects the U.S. but is also gaining speed
in other countries worldwide. The epidemic began with the illegal use of prescription level pain
relievers (Koehl et al., 2019) but is also affected by illicit opiates without the initial prescription
of an opiate. Continued use from desired intoxicating effects may lead to serious physical and
psychological dependence. The number of people affected is continuously rising, as have the
number of those seeking addiction treatment. In 2006, more than 30,000 people lost their lives
lost to opioids and, out of all drug-related deaths, opioids are the leading killer (Genetics Home
Reference, 2017). Over the last ten years, the number of opioid-related deaths increased
significantly, totaling 50,000 deaths (Opiate Addiction, 2020). This number of overdoses
increased by 30% from 2016 to 2017 alone (Collins, 2020), indicating these numbers are
drastically increasing over time.
In 2017, there was a significant increase in opioid-related deaths for 47,600 Americans;
however, there was a slight decline in those deaths in 2018, totaling 46,802. The dependence
problem stems from the over-prescription of pharmaceutical pain relievers that began in the
1990s (Collins, 2020). Opioids were initially intended to treat chronic pain. However, the longterm effects of repeated use and the risk of addiction increased as physicians continued to
prescribe these medications. Over time, when a person's prescriptions ran out, withdrawals
became more frequent. Since the dependence had already been established at this point,
discovering an illicit form at a relatively low cost became the new method to treating the pain.
Nearly 130 individuals die daily in the United States due to an opioid-related death
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(NIDA, 2020). The costs for this crisis are estimated at eighty billion dollars a year for treatment
in healthcare and judicial standings (NIDA, 2020).
Medication-assisted therapy and counseling therapy can have the ability to discontinue
opiate use significantly and overall decrease the number of overdoses that occur each year. This
review examines research concerning opiate addiction and treatment methods of methadone and
buprenorphine to discontinue illicit opiate use. In addition, this study addresses who is
responsible for prescribed medications, whether it be the client in control or physician. This will
gauge whether those prescribed the medication could complete treatment after a certain period of
time successfully without relapsing. Research supports such medication's effectiveness, yet there
is no evidence of why opioid users undergo treatment for an extensive amount of time. This
review will include research from studies on how methadone and buprenorphine treatments are
prescribed and other significant findings specific to the treatments' characteristics. Harm
reduction will play a factor in the research, taking the role of the physicians' alternative approach
when prescribing the medications.
Koehl et al. 's (2019) treatment modality is known as abstinence-based programs, will be
discussed. This treatment modality holds higher success rates for sobriety without medicated
assisted therapy. Counseling therapies reduce the mental suffering of those with opioid use
disorder, develop relapse prevention, and strengthen healthy coping skills. In contrast,
medications-only approaches are found only to decrease the danger associated with
withdrawals.
This research aims to dive deeper into the opioid addiction crisis and educate on the
impacts medicated therapies have on those prescribed through interviews of personal
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experiences. This study will also explain who is in primary control of continued medicated
treatment for opioid addiction. Continuation of medicated therapy questions whether opioid users
are not ready to discontinue or simply abuse the medication-assisted therapy or whether the
concern lies with the prescriber. However, it can be understood there are contradictory truths
amongst all concerns.
This study employs a grounded theory approach. Asking a question to derive a hypothesis
following analysis of the data. The question presented focuses on who is responsible for the
continued prescription of medicated assisted therapy for those diagnosed with an opioid use
disorder? This question is undecided between the client and the physician. Whether physicians
may not begin to taper clients, persuading into a continuous prescription, or whether the
continued treatment is solely up to the client. Contrarily, the physician may not have adequate
knowledge on how to prescribe the medication, and Louie et al (2019) explains some physicians
may not provide adequate services due to the difficulties treating that specific population,
resulting in them being responsible. A final questioning factor is the monetary benefits
physicians receive. As for the client, a recent study indicated that those who preferred methadone
continue use to remain under the opioid's influence. In contrast, those who preferred
buprenorphine wanted to discontinue their drug use altogether and stay abstinent (Bennett,
2011). Lastly, clients may continue their medicated assisted therapy (MAT) prescription by not
completely being ready to make a choice to become abstinent.
To prevent the client from manipulating the assisted therapy programs, the physician
must follow proper treatment guidelines to perform a full assessment. These guidelines provide
knowledge on how to administer medicated assisted therapy and when it is safe to taper the

10
client. However, if a physician does not follow the strict protocol, the clients may abuse the
medications. This may happen if the physician allows the client to remain on the medicine for an
extensive amount of time. There is a blurred area of why a client is on their prescribed treatment
for a long duration, between the responsibility of the client or the physician. Interviews
conducted from the client's perspective can initiate a deeper understanding of why they believe
whether they are responsible for continued treatment or if it is controlled by their physician.
These interviews will discuss what the client personally recommends the duration of the
medication.
This thesis hopes to develop a hypothesis to determine whether the user or the prescriber
causes the presenting issue of continuous treatment and possible action steps to shorten the time
spent on medicated treatment. Making available the firsthand experiences of users in treatment
can develop other studies to help those who struggle with opioid addiction. It is ethically
reasonable to obtain an insider's thoughts to understand the full effects of the treatment it has on
those prescribed. Studying persons with real-life experience can provide an insight into the
struggles associated with medicated treatment therapy and the cultivation of what needs to
change for effective treatment to allow for abstinence without medications.
It is essential to understand the client’s goals when entering treatment. Some may want to
continue using, as stated for those who prefer methadone, but some may want to completely
diminish their addiction and live a life free from addiction and medications. With hopes that
most people want to battle their addiction and establish abstinence, this study will focus on the
goals each participant had going into treatment in addition to their time spent on prescribed
medications.
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Operational Definitions
Antagonist. Does not produce a similar effect as agonists. It can obstruct the opioid from
reaching the receptor that allows for euphoric effects.
Buprenorphine. Partial agonists are prescribed to those with opioid dependence. This
form of treatment is placed under the tongue in a sublingual tablet at low dosage rates.
Full Agonist. Fabricates maximum potential within the brain when activated. Obtains the
same chemistry of partial agonist, however at full potential.
Half-life. Duration of time before the drug removes from the bloodstream.
Harm Reduction: The concept of understanding drug use is apparent, and some are not
able to stop. Allows for death reduction by keeping people alive by still obtaining the ability to
use but in a safer manner (E.g., safe/clean needle exchange to prevent HIV, safe doses to avoid
overdosing).
Length of time in treatment. The duration client is active in treatment with medicated
assisted therapy.
Medicated Assisted Treatment (MAT). Use of medications and therapy for the
treatment of opioid use disorder.
Methadone. Full agonist that acquires longer-lasting effects than regular opioids to aid in
the treatment for opioid addiction.
Mu-opioid receptor. Receptors located in the amygdala release dopamine, reinforcing
pleasure, and rewards systems within the brain.
Opioid/Opiate. A substance that produces a euphoric like experience in a user, nearly for
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alleviating pain. Found in prescription medications (oxycodone, codeine, morphine) or
illicit versions (heroin).
Opioid Use Disorder. Self-administering of an opiate that no longer serves for medicinal
reasons such as injury. The disorder characterizes obsessive thoughts and actions towards using
an illicit drug. Users have elevated tolerance and dosage to obtain a euphoric experience.
Withdrawals are prevalent if the user does not continue the administration of the drug.
Partial Agonist. Attaches to receptors within the brain to partially activate the opioid
receptors.
Pharmacotherapy. The treatment of a disease through the administration of drugs.
Taper. The gradual decrease in methadone or buprenorphine.
*Definitions cited from Substance Abuse and Mental Health Services Administration (2018) and American
Psychiatric Association DSM V (2013).
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Chapter II: Background
Opioids began with the intent to aid in pain management, post-surgery, or any intense
medical procedure. Common prescription opioids include morphine, hydromorphone, codeine,
oxycodone, and hydrocodone. Street opioids include heroin and fentanyl (Strum, 2020). Most
opiate addiction starts when a person sees a physician who prescribes prescription medication to
aid in chronic pain. Jones and McCance-Katz (2018) state in their research regarding the opioid
history and strategies for pain management that prescribing doctors are fully aware of the issue at
hand and are continuing to be an active member in the crisis. The issue is, there is no evidence
for long-term treatment to aid in chronic pain to this date. The problem of chronic distress causes
conflict from one prescriber to another. Some may have good intentions to help the population,
whereas some physicians lack this quality, yet some may have those positive intentions yet make
wrong choices. Physicians that did not use opioids for treatment were shamed and told they were
unethical and "inhumane" for not prescribing pain medications for those in need. This led to
many more physicians prescribing opioids to diminish the stigma attached to medical doctors
(Jones et al., 2018). However, negative stigmas were still found to be attached to those
associated with the disapproval of continuous prescriptions. Prescribing one an opioid for pain
following a discontinue in their medication may lead them to the illicit forms (Lahey, 2016),
causing them to become even more addicted.
The presenting issue that remains is that many people may become addicted if they
continue prescription use and gradually turn towards illicit ones such as heroin when these
prescriptions are discontinued and when the onset of withdrawal is experienced. As mentioned
previously, illegal use is exacerbated by the low cost and the fact that these drugs are readily
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available on the streets (Opiate Addiction, 2020). Other factors associated with opiate addiction
relate to prior drug use, certain personality traits, and undergoing traumatic upbringing (Genetics
Home Reference, 2017; Somer, 2005). As these types of drugs are continued over long periods
of time, changes in brain chemistry occur, which leads to psychological and physical dependence
that then creates unwanted withdrawals when abruptly discontinued.
When people become addicted to opiates, many changes occur within their brains. Upon
entering the bloodstream, the drug mimics the nervous system's receptors on our learned
behaviors, the reward center, and pain receptors (Genetics Home Reference, 2017). The primary
receptor the opiate attaches to is the mu-opioid receptor. Upon administration, it mimics this
receptor, opening voltage-gated channels in the synaptic membrane to release dopamine. When it
releases dopamine, it releases an extensive amount, acting as a reinforcer (Mistry et al., 2014).
This reinforcer establishes a connection between the substance and the brain for needed repeated
use to develop that feeling of euphoria. Upon first use, the user may only experience the highest
intensity of that feeling. The only way to feel that close of euphoria is by using the drug again.
With repeated use, the brain ceases to create more dopamine (Opiate Addiction, 2020) creating a
cycle of continued use to experience pleasure and avoid pain. Since the brain now has difficulty
producing a healthy dopamine level, it makes the dependence often visible within users and
addicts, such as pale skin, weight loss, needle marks, and isolation. The drug then alters the
brain's neuroplasticity (Mistry et al., 2014). The brain relies on that drug to provide it with that
external dopamine release, which then changes the brain cells (Opiate Addiction, 2020). Without
that reliance, painful withdrawal is experienced, which consumes the body physically and
mentally.
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Some people are more vulnerable to addiction than others. For those who are more
susceptible, after a few consecutive repeated uses, addiction takes over, leaving one with
increased tolerance and dependence (Opiate Addiction, 2020). These drugs have an intense and
powerful effect on the brain, as stated, making it difficult not to use them (Genetics Home
Reference, 2017). Opioid addiction is fast due to the strength and changes that occur rapidly
within the brain. Once the habit becomes established, it is a long road to recovery. The user may
quit cold turkey, but typically they will gradually taper off the drug; otherwise, they will
experience withdrawals that can be unbearable. Withdrawals can be painful, including nausea,
depressed mood, insomnia, vomiting, cold sweats, and difficulty eating (Mistry et al., 2014).
Often repeated relapse is seen due to the powerful cravings, painful withdrawals, lack of healthy
coping skills, and altered brain plasticity. However, an alternative method for treating those who
have acquired dependence on these substances with extreme withdrawal symptoms.
The most commonly prescribed medicated therapies in a clinic are methadone and
buprenorphine. Although these medications are the most commonly prescribed, research found
that medicated assisted therapy is deemed "underutilized" (Jones, McCance-Katz, 2018), due to
the lack of education on how to prescribe the medications properly. Besides medications,
clinicians often recommend that clients participate in counseling therapy to establish skills
specific to relapse and understand triggers that initiate the relapse. Jones and McCance-Katz
(2018) indicate an effort in educational training for prescribers to require a therapeutic setting for
treatment to work effectively. However, since there is minimal knowledge acquired, this causes a
decrease in the agreement to prescribe the medications.
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Before administering medicated therapy, the clinician needs to understand where the
client is at with withdrawal experiences. When determining the severity of withdrawal, clients
differ from one another on physical effects and intensity. One may experience detrimental and
unbearable withdrawals, whereas one may believe they are manageable. To effectively determine
how severe the withdrawals are, the clinician will present the client with a Clinical Opiate
Withdrawal Scale, formally known as "COWS" (Koehl et al., 2019). This assessment is used
before medicating to determine how much medication is necessary for the initial administration
dose and continued treatment.
Wesson and Ling (2003), the COWS founding creators, inform readers of its
implications. Dr. Wesson developed the scale to distinguish withdrawal from intoxication
(Tompkins et al., 2009). Some physical symptoms may present as either under the opiate's
influence or as withdrawals from the lack of opiates. This scale asks questions based on pulse
rate, gastrointestinal symptoms, if they experience any tremors, sweating, restlessness, body
aches, runny nose or eyes, anxiousness or irritability, and dilation of the pupils (Wesson & Ling,
2003). Tompkins et al. (2009) performed a validity study to determine whether the scale was
reliable and valid when cultivating results from mild to severe withdrawals. As this scale helps
determine the severity of physical dependence established in the user, it was consistent with
measuring and identifying the symptoms across time by following the distress and determination
of whether the symptoms were increasing or decreasing with the continuation and
discontinuation of use. The study found that the scale was highly accurate when administered to
opiate users.
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In addition to withdrawal severity, specific medication doses are determined and
administered to achieve stability – meaning not sedated nor experiencing withdrawals. To
determine whether a client has achieved stability, the clinician must observe whether the client
has officially met a balance in their life. The client must report a clean urine analysis (UA) to
ensure they are no longer using illicit opioids. The clean urine must accompany no present
cravings in addition to a decrease in withdrawal symptoms, physically and mentally (SAMHSA,
2018). Along with medicated therapy, it is recommended that clients participate in group and
individual therapy sessions that implement psychosocial counseling, relapse prevention, coping
skills, and potential trigger strategies to aid in a successful recovery (Jones et al., 2018).
Medications alone will not cure the addiction. However, they will aid in the physical discomfort
of withdrawals that many are reinforced to avoid by continuing using.
Within the medical field, practitioners treat medical concerns through the concept of
harm reduction. Harm reduction can often be viewed as an approach to establish a healthy
balance in the person's life without causing harm (Kalk, 2018). Regarding opioid use disorder,
this may include allowing the person to continue using at a safe needle exchange program that
promotes healthy use if they choose to use it. Clients who participate in harm reduction may find
themselves utilizing services available to them. These services include safe needle exchanges,
MAT for clean, uncut drugs, and promote encouragement of progress towards abstinence
(Williams, 2019). Since drug use will always be prevalent, the harm reduction approach, often
used for other medical illnesses, began to help decrease overdose rates associated with those who
still want to use opiates.
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Harm reduction approaches for opioid use disorder are applied to decrease deaths and
save people from overdosing. Medication therapy was introduced under this approach as a form
of alternative to aid in treating opioid use disorder for those who want to continue use. The
increase of medicated assisted therapy allows opioid users to medicate safely, including clean
needles to avoid the spread of HIV and Hepatitis C, proper dosage to prevent overdose, and
maintain withdrawals (Collins, 2020). With this, a significant decline in illicit opioid use and
risky behaviors associated with the user is reported (SAMHSA, 2018; Livingston et al., 2017).
However, it has been proven that opioid seekers tend to use the system to acquire a
cheap, pure high to avoid withdrawal symptoms. These people are aware of the low cost of
medications, easy access, and additional doses guaranteed upon beginning this type of treatment.
Bennett (2011) states, as the heroin price increases on the streets, the quality reduces. In some
areas, the high price keeps the drugs from being readily available, increasing the addict's chance
of experiencing painful withdrawals. Medicated assisted therapies available for opioid users are
becoming readily available due to government funding and providing a safer alternative for a
constant clean high. The drug quality of these therapies is approximately 98-99%. With that
information, this means the user, if seeking sedation can remain sedated as pleased without the
risk of withdrawal and at a low cost. However, some may not seek the sedation yet remain
vulnerable to becoming sedated when administered.
As this approach can benefit those who want to continue use, there are pitfalls associated
with clinics that practice harm reduction. Clinics are often hot areas for dealers and users to
locate and use (Williams, 2019). Generating an area of previous users, this can cause conflict and
triggers for those aiming for abstinence. From a prescriber's perspective, it is often noticed that
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the client's goals are disregarded (Kalk, 2018). If one has the goal of abstinence, but the
prescriber practices harm reduction, the client may never see life without a dependence.
However, those clients who often push for abstinence at an early stage are often seen as most
vulnerable to relapse. The prescriber must keep reanalyzing the client to ensure they understand
the client's goals since abstinence and harm reduction are viewed at opposite sides of recovery.
Nevertheless, those who do not receive medicated treatment or counseling therapy maintain their
likelihood of remaining addicted.
Anecdotal evidence mentions that the addict goes from paying a dealer to paying
pharmacies, yet their addiction does not subside. The addiction is then viewed as being replaced
by a pharmaceutical and now not allowing for abstinence from overall opioid use. Bennett
(2011) states that instead of healing the addiction, medicated therapy continues the dependency.
Aside from harm reduction, this notion is yet a significant concern whether the physician is
responsible. Is the physician keeping a client on MAT for monetary gain?
Pharmaceutical companies benefit heavily from the number of medications administered
to the community (Jones & McCance-Katz, 2018). This notion questions whether the intent to
diminish opioid use is to transfer users from illicit form to licit instead of the goal of abstinence.
Livingston et al. (2018) claim within their qualitative study that with an increase in kickbacks to
physicians who prescribe opioids, they begin to provide non-effective services to their clients.
Koehl et al. (2019) discussed misapprehension regarding prescribing and an absence of
knowledge to prescribe, which can be the primary source of issues providers may encounter.
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Pharmacotherapy for Opioid Use Disorder
The following section discusses the history of MAT and how methadone and
buprenorphine work physically and mentally as an opioid treatment therapy. Also, research will
be reviewed regarding these medications' outcomes to understand the benefits of their use
further.
Methadone
Treatment may be essential for those who have addiction problems, especially those who
become dependent, physically and mentally on a substance. Scientists and doctors have teamed
up to create a medicated-assisted treatment to limit drug use with tapering methods. Methadone
was the first "long-term treatment" drug to aid in opioid addiction, founded in 1965 (Levran et
al., 2012; Ali et al., 2017; SAMHSA, 2018). This medication is known for its long-term
commitment and viewed as having a "ball and chain" effect, meaning that it limits one's freedom
to live a life free from the medication (Livingston et al., 2017). Bennet (2017) stated,
"methadone maintenance could serve as an indefinite "holding device" for those unable to give
up opiates but would be willing to be maintained on methadone and reduce illegal use of drugs"
(p. 133). Thus, the person would still be connected to a substance, thus supporting the notion of a
ball and chain effect.
Methadone is a mu-opioid receptor full agonist, meaning it causes the same effect as
opioids when consumed. Methadone is an artificial opioid administered to discontinue illicit
opioid use and decrease cravings and withdrawal symptoms (Levran et al., 2012; Kayman et al.,
2006; SAMHSA, 2018). During treatment with proper dosing, this substitute supports the body
with withdrawal prevention and helps return the brain to homeostasis, allowing the user to
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discontinue illicit opiate use (White, 2012). With each week of prescribed treatment, the user
slowly weans off the illegal drug and continues to use methadone. Eventually, this process is
followed by a progressive decrease in methadone consumption, known as a taper.
The half-life of methadone, dependent on users, averages 24 hours, with eight being
minimal and 59 being the most extended to be reported. Peak effects were noted between hours 2
and 4 (Koehl et al., 2019). However, upon initial dose, those prescribed do not experience the
full effect of the drugs until approximately day four. Prescribers found no maximum effect of the
prescription as doses are increased – allowing for increased sedation with increased amounts.
Like all medications, methadone has potential risks and side effects associated with use. The
most detrimental risk is developing physical dependence from long-term use. Internal threats
may include a higher chance of constipation, respiratory depression, arrhythmia, hypoglycemia,
and hypotension (Koehl et al., 2019).
According to the Substance Abuse and Mental Health Services Administration (2018)
and Koehl et al. (2019), there are established guidelines in proper administering methadone. The
initial dose of 5-10mg should begin slowly with a gradual increase every three to four days.
Once the client has reached stability between sedation and withdrawals, the clinician continues
administration, lengthening the duration between dosing to expand the time unaccompanied by
cravings and withdrawals. Stable doses are typically an average of 60mg. This level of dosing
has the best retention rate amongst users. Clinicians may administer higher doses to
approximately 120mg, dependent on withdrawal and addiction severity. Once the client reaches
consistent stability, the taper is then initiated, beginning at a 5-10mg decrease until a low dose is
achieved. If this is successful, they may switch to BUP to allow for a smoother transition to be
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completely off medications and follow a successful recovery. If a client chooses to withdraw
from medication therapy without taper, the chances of relapse with potential overdose and death
increase significantly to approximately 90% (Velander, 2018). Symptoms of withdrawal and
cravings are still present, but the tolerance established before MAT decreased. Some are not
aware of the significant decrease in tolerance and if they relapse, they may overdose causing
potential death. However, those who do not initiate a taper and continue long-term use may be at
risk of developing a physical dependence on methadone.
Studies have found that the higher the dosage of methadone, the more substantial the
decrease in illicit drug use (Kayman et al., 2006). According to Ali et al. (2017), when
comparing methadone to heroin, it is not as damaging. However, there are no exact guidelines
for how long the user should be on methadone (Kayman et al., 2006). Since there are no
guidelines for the length of treatment, the focus of this study helps determine who is responsible
for the continued MAT. Issues have been known to arise when replacing illicit use with
pharmaceutical dependence, questioning why there is no exact length of treatment. The
misunderstanding is associated with not completely knowing when a client is stable since
methadone produces sedating effects. According to Bennet (2011), methadone should only be
prescribed to patients when they have already obtained a physical dependence on an opiate. If
physical dependence is not prevalent within a patient's life, prescribing methadone may cause
more addiction issues.
Aside from the pharmaceutical aspects, methadone maintenance therapy strongly
suggests counseling support to avoid replacing one addiction with the other. Meaning, when
participating in this type of treatment, the user cannot only take methadone to diminish the

23
dependence; they should participate in counseling to see significant results firsthand. Those who
withdraw from counseling therapy are increasingly vulnerable to relapsing (Schwartz et al.,
2016).
Many stigmas have developed over time since the introduction of methadone half a
century ago. According to White (2012), people believe that a user has not begun their recovery
when using methadone but, instead believes that they start their recovery once they are off the
methadone. These stigmas have caused extreme views and opinions regarding the treatment
therapy. McElrath and Joseph (2017) also believe that it "reinforces" drug use rather than
understanding that methadone is a part of the treatment and recovery process, which is then
viewed as taking the place of an illicit addiction to a pharmaceutical addiction. (Louie et al.,
2019). To conclude, there are negatives and positives associated with methadone maintenance.
Some are pro methadone, whereas some are against the prescribed medication (Bennet, 2011).
With scientists continuously growing research and aims to avoid stigmas, the following
section will discuss how buprenorphine was introduced as an alternative and less harmful agent
to treat opioid use disorder.
Buprenorphine
More recently, doctors have developed an alternative method for opioid addiction called
buprenorphine (BUP), or Subutex. This drug, introduced in 2001, is similar to methadone. This
medication therapy is highly suggested for people who have opioid use disorder. The pitfall is
that it is only available in urban areas. People with this disorder may lack available treatment in
rural areas may come into conflict with a need to treat their addiction (Koehl et al., 2019). Unlike
methadone, BUP is a mixed mu-opioid receptor partial agonist, meaning it only provides the
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brain with partial intoxication. (Burns et al., 2015; Milne et al., 2009). When absorbed, BUP
vigorously attaches to the opioid receptor to avoid other opioid bindings (SAMHSA, 2018). This
drug does not allow the person prescribed to use other opiates while taking this medication; they
will not experience effects simultaneously.
Buprenorphine has a "ceiling effect" with maximum doses, establishing security for a
safer boundary when administered. It provides no euphoric effect, unlike the alternative,
methadone (Koehl et al., 2019). The purpose of BUP is to treat and detoxify opioid addicts from
the illicit drug they used and provide them with stability from withdrawals and dependence
without sedation (Louie et al., 2019). However, this medication can develop a physical
dependence on the user with long-term use. If discontinued abruptly, those prescribed may
experience withdrawal, which again supports why a taper is highly suggested (SAMHSA, 2018).
Introduced in 2006, naloxone (NAL), a mu-opioid antagonist, has been combined with
BUP and was popularized for its effectiveness in opioid replacement therapy (Burns et al., 2014).
BUP/NAL, formally known as suboxone, is administered as a sublingual tablet, coming in two
doses. BUP administration starts at 8mg and NAL at 2mg. Once the stability is established, an
additional prescription at a slightly lower dose creates a taper in the prescription with BUP at
2mg and the NAL at 0.5mg (Milne et al., 2009). A significant factor of this medication is that the
half-life is around 37 hours, with a 24 to 69-hour average, disconnecting at a slower rate versus
methadone's half-life of roughly 24 hours (Sansone & Sansone, 2015). Longer half-lives allow
for less dosing and a mental disconnect from continued dosing, allowing for significantly lower
rates of illicit drug use due to the higher duration of the half-life and inability to experience the
other drugs’ effects.
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The Substance Abuse and Mental Health Services Administration publishes guidelines on
how to administer BUP in addition to methadone. Upon initial prescription, the first dose is
prescribed at 2-4mg with two-hour supervision of the patients' response to the medication. The
clinician may administer an additional amount if the patient is still experiencing withdrawal. The
user may experience withdrawals for up to twelve hours. Upon beginning the medicated
treatment, BUP is administered on a Monday, Wednesday, and Friday basis. Extended time is
due to the extended half-life of the drug. Like methadone, proper dosing is achieved when the
drug provides the patient with stability from craving and withdrawals without being sedated.
Once the patient has acquired a stable balance between decreased withdrawals and
craving, the clinician actively begins the taper. The Substance Abuse and Mental Health Services
Administration (2018) implies that the taper starts by reducing the dose to 5mg with an extended
time between administering an additional amount. It suggests significant results are established
at a maximum dose of 30mg, where the taper begins. A downfall to starting the taper is that it is
solely up to the client. Meaning that even though they are stable, they may not want to begin the
taper. To avoid this, the clinician should educate the patient and encourage them to start their
taper once stability is achieved.
For a clinician to prescribe BUP, they must first receive a waiver before providing
services. Eligibility to obtain the release is through the Substance Abuse and Mental Health
Services Administration (SAMHSA). The administration, as of 2018, grants physicians the
authority to prescribe up to 275 patients BUP. However, those who obtain a waiver are reluctant
to prescribe due to their attitudes regarding the population (Louie et al., 2019). This belief may
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be due to the physicians’ lack of education and their own opinions and biases. Those who lack
the knowledge may pose a barrier in their treatment approach (Koehl et al., 2019).
Recent studies from Burns et al. (2014) and McElrath and Joseph (2017) have found that
BUP has positive effects for those who willingly want to discontinue opiate use. The willingness
could be associated with the significantly lower doses administered, concluding that this drug
may be a better option for those who do not want to consume many treatment dosages (Burns et
al., 2014). McElrath and Joseph (2017) state that users will experience fewer depression
symptoms in a single dose. Users report they are also associated with a lower risk of illicit drug
use and side effects. Reports also note that participants found it easier to engage in treatment
when not forced and the opportunity to openly attend counseling treatment, which then leads to
higher attendance rates. Other studies report that buprenorphine increases their overall quality of
life. Mitchell et al. (2015) studied the four major domains of life on buprenorphine effects –
social, environmental, psychological, and physical. He found a statistically significant increase in
each domain when participating in this type of treatment. These positive attributes leave people
feeling more comfortable when seeking out treatment rather than being stigmatized. This study,
however, did not include at what time length clients reported a higher quality of life.
Much like all pharmaceuticals, there were some adverse effects found with the use of
buprenorphine. Difficulty breathing and the likelihood of overdosing are uncommon; however, it
is experienced with other opioid and IV use (Koehl et al., 2019). They also discovered that when
undergoing treatment with other drugs, the medicated treatment can cause sedation within the
patient. According to Burnes et al. (2014), the recovery rates for those undergoing this treatment
are lower due to their first experience's unpleasantness. This could correlate with the
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significantly low dosage administered. Users typically use large amounts of illicit drugs every
day. When decreased drastically to a lower dose, this can cause uncomfortable feelings—
withdrawal symptoms such as nausea and vomiting. Studies have shown, indeed lower retention
rates in BUP due to the patient not experiencing intoxication as found when using methadone
(Bishop et al., 2018).
Oftentimes, users undergo both types of treatment. When under the influence of
methadone, they experience similar feelings as when using the illicit form. However, when using
buprenorphine, they typically do not have the same physical and mental experience when using
methadone or illegal forms. The following section will discuss research conducted on MAT's
effectiveness, with highlighting the time attributed to being on MAT.
Effectiveness of MAT
When focusing on methadone, a study found that those who do not want to abstain from
opiate use prefer methadone treatment, primarily due to the intoxicating experience (Bishop et
al., 2018). A second study to solidify those findings conducted by Burnes et al. (2014)
discovered that those who initially started on buprenorphine for treatment had transferred to
methadone more often than those on methadone had transferred to BUP. This statistic found that
the doses are smaller with BUP, and the euphoria experienced was not as powerful as with
methadone due to the withdrawals from the initial taper. The Substance Abuse and Mental
Health Services Administration (2018) also verifies that switching from BUP to methadone is
significantly more remarkable due to the desire to avoid withdrawals. As stated previously, BUP
does not provide a user with the sedating intensity experienced from methadone or the drug of
choice. When interpreting the results of those who switched from BUP to methadone, the
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euphoric feeling was not equivalent to the illicit experience. This study, however, did not
mention how long a person had prescribed the medications or what time frame they switched
between the medicines, or when the euphoric feeling was established.
From a BUP perspective, Milne et al. (2009) deemed this treatment safer to use than
methadone. The side effects of dependence, nausea, and vomiting are significantly lower with
BUP due to the lowered dosages administered. Bishop, Gilmour, and Deering (2018) found that
it was also more comfortable to withdraw after treatment was complete than when using the
methadone treatment. According to Hser et al. (2013), those who pursued BUP treatment had a
much more positive experience than those who chose the methadone treatment. However, the
study conducted by Blum et al. (2017) found that the success rate amongst the two is similar.
Nevertheless, both medications show improvement with a decrease in illicit drug use by the
addicts undergoing treatment. Granted the findings of success rates for BUP, there was still no
valued time frame of how long these participants were prescribed the medication to achieve
successful withdrawal and report positive feedback.
When comparing studies conducted on each treatment drug, methadone had a better
retention rate than buprenorphine. Methadone was the preferred treatment method due to the user
experiencing sedating effects. The limitation of this conclusion is specific to the dosage given to
the patient. Methadone has a significantly higher dose than buprenorphine, making the retention
rates higher for that drug. SAMHSA (2018) found that those prescribed methadone stay with
treatment longer than those prescribed BUP. The reason being it is harder to taper off MET. It is
questioned whether testing is performed to determine whether methadone doses can be
equivalent to buprenorphine doses: either lower or higher. Although both substances deem high
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retention rates from illicit opioid use, there was no provided therapeutic time frame from these
results.
In addition to retention rates, attention is also focused on the dosage amounts. When
administered either drug, there was a significant difference in how much of the dosage one
received. The lowest amount generally delivered for methadone is 60mg. One study showed an
80% retention rate when given that specific amount. When given the highest dose of 120mg, the
retention rate increased to 91%. As for buprenorphine, Hser et al. (2013) claimed that BUP's
highest retention rate was only 60% on its highest dose of 32mg. Those numbers reflect the
findings of those undergoing methadone treatment having 50% better chances of staying in
treatment than BUP. This study implies that if treatment facilities increased the dose of BUP,
perhaps to that of methadone, would retention rates increase? Although the amounts are studied
heavily, there was no significance associated with how long they are administered to establish
those retention rates.
While studies have shown that methadone has better retention rates, buprenorphine has a
higher potential for true success. The quality of BUP administered is lower than that of
methadone. These studies also conclude that there is a potential to be entirely off both illicit and
treatment drugs when using buprenorphine. Methadone, however, does have the potential for
aiding in the termination of illegal opioid use but is limited to complete termination of the
medication. Koehl et al. (2018) suggest that BUP is preferred over methadone because of its
adaptability. Allowing the client to remain in a stable state without withdrawals and sedation.
There is also a preference for BUP due to the significantly low side effects experienced when
undergoing treatment compared to methadone. However, the study states there is no evidence on
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which drug deems to be superior to the other. Overall, both drugs show a significant contribution
to overcoming opioid addiction. Again, granted research has found MAT effective to discontinue
illicit use; there was still no duration for how long these participants were prescribed to establish
the discontinuation of illegal use and terminate the medication.
According to the Substance Abuse and Mental Health Services Administration (2018),
when prescribing methadone or buprenorphine, the longer time spent prescribed MAT, the
higher the success rates of discontinuing illicit use. Before continuing long term, the physician
must consider the needs and goals of the client. In addition to MAT's continuation, a research
study conducted on MAT mortality found an average time length of those prescribed MET and
BUP. Those prescribed methadone therapies were averaged 363 days and 173 days for
buprenorphine (Hickman et al., 2018). This study indicated that the average time for those to
establish low morality levels was around the year and half-year mark. This information is
essential to note that there are noticeable changes within the client around those milestones and
perhaps consider beginning the taper at the point. However, it did not mention whether the length
of time was therapeutic and did not include any additional information regarding time spent in
treatment.
To conclude, there is a significant potential associated with medicated assisted treatment
to deplete opioid addiction. However, it is essential to note that psychotherapy should be
encouraged while engaging in medicated assisted treatment to provide optimal outcomes. The
lack of focus with each medicated assisted treatment is when these participants have been
prescribed the medication is, for how long they were prescribed when effectiveness is
established, and if they have enrolled in psychotherapy. Indeed, the results are positive and have
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been proven to increase life satisfaction compared to what they may have been before the MAT;
it is important to focus on the time frame for therapeutic effectiveness.
As mentioned, this study aims to understand why opioid users are undergoing treatment
for an extensive time when there are proper guidelines to taper a client from the medicated
treatment. The Substance Abuse and Mental Health Services Administration (2018) provides
physicians with the understanding and knowledge on how to properly administer each of the
medicated treatments for opioid use disorder and how to decrease the medication of a taper to the
eventual discontinuation of opioid use ultimately. Treatment protocol discusses what doses are
administered for each prescription, dependent on the client's physical dependence and sedation
level upon administration, including where the dose amount should begin, how to increase the
dose gradually, and where and when to stop growing. The increase remains until withdrawals are
managed and sedation is no longer. Following the plateau of the rise comes the decrease, which
is when the taper begins. The protocol ensures how to accurately understand when to decrease
the prescription and address the withdrawal and sedation levels, yet the time frame of when these
interventions of taper being initiated are not looked at enough. It questions whether there is a
lack of knowledge and education in the prescriber on administering medication correctly or if the
client is withholding information to lengthen the medicating process.
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Chapter III: Methods
The research in this study implemented qualitative findings derived from interviews with
people previously prescribed one of the medicated opioid use disorder treatments previously
discussed. Interviews focused on life experiences and perspectives regarding the length of their
prescribed treatment. Data collected was used to develop an in-depth insight into why those
prescribed MAT had to undergo long-term treatment. Chapter IV will review the results and
summary of the data as written and perceived by the researcher.
The Institutional Review Board approved this study from Saint Cloud State University.
Participants
This study obtained five adult participants, one of whom had experience with prescribed
methadone and four with buprenorphine. Participants were either currently taking these
medications or have done so in the recent past. Some also had experience with both drugs. The
participants were recruited from various Minnesota locations and volunteered to be a part of this
study. There was no stipulation as to the dosage amount used for their treatment or length of
treatment. Drug of choice documentation, how long they were actively addicted, what MAT they
received, and if they received any counseling services while undergoing MAT was provided (see
Table 2). Maximum doses prescribed are included to provide additional conclusions when
comparing other information (see Table 3). It is believed that those characteristics place value on
opinions and beliefs regarding treatment regimens.
Participants asked to participate, engaged in a one-on-one interview with the researcher,
and were encouraged to provide truthful content to establish factual findings in this study. Each

33
participant was provided the opportunity to withdraw or take a break from the interview if any
discomfort was experienced. Referrals for treatment help were provided upon request.
Design and Procedure
Based on a grounded theory approach, this study used an analysis-based design focusing
on the time spent with medicated assisted therapy to examine treatment perceptions—the
primary data will be qualitative, collected by semi-structured interviewing. Data were collected
from participants through face-to-face interviews via Zoom. Open-ended baseline questions
gathered information regarding the participant's treatment, experiences, and perceptions
regarding treatment. Private and confidential interviews were established to ensure a willingness
to provide the researcher with accurate information. Quantitative data were collected to establish
a fundamental understanding ground of each participant and their experiences. Quantitative data
includes dosage, length of medicated treatment, length of active addition, drug of choice, and
prescribed medicated assisted therapy.
Interviews lasted approximately one hour and were recorded for transcription purposes.
All interviewees were required to complete a consent form before questioning. Interviews were
then transcribed to form codes to analyze the collected data. Based on grounded theory, this
approach will help formulate a hypothesis regarding the data collected from participants.
Participants answered similar questions based on their treatment to examine different themes and
categories. Additional probing was performed to gather additional information regarding their
length of treatment. These findings were placed into similar and different groups based on
relevant information. The primary focus is given to the thoughts and opinions regarding their
treatment length. The researcher will question how they felt about receiving treatment for as long
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as they did/are and their beliefs on whether they thought they were in control of their treatment
or if the physician was.
Measures
Upon questioning, participants provided information on what treatment was prescribed.
They answered how long they have been on MAT and which medication they received. This
information placed them into groups to find the similarities and differences between the
responses provided. Another question asked was regarding their dosage of treatment and the
maximum dose received. After collecting characteristic information, participants were asked,
“what goals did you have entering medicated treatment?” “Do you believe being on MAT for
your duration was/is effective?” “Was the length of time a form of harm reduction?” Additional
questions regarding the role of their physicians were asked to break the barrier between who is
responsible. Opinions regarding counseling services were also gathered. Lastly, thoughts and
opinions for an opioid-dependent to be prescribed MAT for a certain amount of time was
provided. Answers were noted and further analyzed by coding. Those who have been in therapy
a long time will be asked if they see themselves coming off the medicated treatment anytime
soon. Since this study is founded on semi-structured questions, the questions will begin similarly.
However, once probing begins, data will be collected with questions specific to the individual.
Analysis
Upon completing the interviews, data were transcribed and coded, which placed
participants responses into thematic groups. Codes were also combined to create different
categories and themes to compare treatment types. The information focused on the differences
and similarities in the length of their treatment experience.

35
NVivo coding system was used to aid in transcription and coding for recursive themes.
This program placed data collected into a node to develop several codes specific to the interview
responses. This method helped the researcher organize and analyze the data to combine
participant experiences for further conclusion. All codes were given functional definitions to
describe each participant's experiences that were similar and dissimilar. Post coding, a review of
information and literature was required to ensure the coding was correct and the conclusion is
accurate.
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Chapter IV: Results
This chapter details the results analyzed from interviews conducted on those prescribed
methadone or buprenorphine for opioid use disorder. Characteristics of the participants will be
discussed through tables, and the results through qualitative quotes and codes developed from
NVivo. A collective summary of the results will be provided at the end of this chapter. To begin,
Table 1 describes participant characteristics to develop an understanding of the demographics of
each participant. Table 2 explains the percentages attributed with Table 1 in addition to
information not provided in Table 1. Table 3 provides an explanation of the prescribed doses
over what years. This information will be discussed at the end of the chapter. Table 4 indicates a
percentage of participants deem responsible for their treatment for how long they have been
prescribed the medication. Lastly, Table 5 indicates a representation of client perspectives on
how long one should be maintained on MAT to recover from opioid use disorder.
Characteristics of the Sample
Table 1
Participant Characteristics with MAT
Participant Age Length of

MAT Years Prescribed

Addiction

1

28

6 years

2

42

3

24

2 years

4

36

5

33

Year Counseling

of

Dose Started

MAT

MAT

for OUD

Suboxone

1

16mg

2020

Yes

21 years Methadone

2

200mg

2012

Yes

Suboxone

3

16mg

2018

No

13 years

Suboxone

4

32mg

2012

No

10 years

Suboxone

5

24mg

2016

No
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Table 2
Characteristic Percentages (n= 5)
Characteristics
Gender
Male
Female

N

%

2
3

40%
60%

Age
20-25 years
26-30 years
31-36 years
36-40 years
41-45 years

1
1
1
1
1

20%
20%
20%
20%
20%

Drug of Choice
Heroin*
Pills*
Fentanyl

3
3
1

60%
60%
20%

Length of Addiction
0-5 years
6-10 years
11-15 years
16-20 years
21-25 years

1
1
1
1
1

20%
20%
20%
20%
20%

Medicated Assisted Therapy (MAT)
Suboxone
Methadone

4
1

80%
20%

Length of MAT
0-1 year
2-3 years
4-5 years

1
2
2

20%
40%
40%

Received Counseling for OUD
Yes
No

2
3

40%
60%

*Two participants obtained two drugs of choice.
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Table 3
Participant Prescription Data
Participant

MAT

Prescribed Dose Years Prescribed

1

Suboxone

16mg

2020-present

2

Methadone

200mg*

2012-2014

3

Suboxone

16mg

2018-present

4

Suboxone

32mg*

2012-2016

5

Suboxone

24mg

2016-present

*Suboxone recommended doses: <30mg
*Methadone recommended doses: <120mg

Tables 1 and 2 explain the characteristics viewed in this study to develop an
understanding of each participant's background specific to their addiction, drug of choice,
medicated treatment, length prescribed MAT, how long they were prescribed, and so on. This
provided the researcher with information to refer to when comparing the data provided by each
participant. The average length of treatment in the study was three years, with a participant
prescribed for only one year, and one prescribed for five years.
Of the 5 participants (two male, three female), 4 (80%) have been prescribed suboxone,
and 1 (20%) prescribed methadone. Between ages 36 and 45, two of the participants have been
prescribed over the recommended MAT doses and began treatment in 2012. The additional three
participants, between 20 and 36, are currently prescribed within the recommended dose range
and have initiated treatment within the past five years. Each participant reports obtaining
different drug choices, two of which held pills to be their first addiction, followed by heroin.
Two of the three participants received counseling for opioid use disorder, one of which reports
not receiving supplementary services. The following three participants report receiving MAT
without OUD counseling services.
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As the study primarily focuses on time, data was analyzed on recursive themes regarding
physician’s role and participant’s role in treatment to formulate observations on who is primarily
taking more responsibility for the length of time in treatment. The main themes focused on
include physician-related factors, participant-related factors, opinions, and recommendations for
length of treatment. Refer to Table 4 for a visual representation of client perspectives on who
they believe was in control of the length of their treatment.
Physician-related factors
Harm Reduction. During each interview, participants were educated on harm reduction
strategies and why the medical field uses them to deal with medical concerns. Participants 2 and
4 believed the MAT was not a form of harm reduction. Participant 4 stated, “There was no harm
reduction being on methadone. Methadone for me was not a treatment; it was an addiction.”
Both participants continued on MAT at higher than the recommended doses for their entire
treatment. They also noted the withdrawals were significantly worse than coming off of their
drug of choice alone. One participant suggested that why would this be a form of harm reduction
if it is worse than illicit use? Participants 3 and 5 reported they believe their treatment is a form
of harm reduction due to decreased going backward with their recovery, and their physicians do
not want to see them fail. However, participant 3 questioned “why are the withdrawals worse
then?” This question was asked due to trying to understand the concept of harm reduction and
why it would be applied to treatment if there is more harm done once discontinuing the
treatment. Participant 1 did not report on harm reduction due to early initiation of treatment and
believe they control their treatment.
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Monetary Motivation. A perception of the participants was that their treatment length
may have been continued due to increased benefits for the physician. This recursive theme was
held for 60% of participants that the physician is primarily responsible for continuing their
treatment longer than necessary. Of course, it is not certain this is the sole reasoning, but it was
mentioned enough to provide a section on the theme. Participant 4 mentioned that continuing
treatment was “filling his (the physicians) pockets.” They then questioned, “I don’t see why you
would maintain somebody for that long if there weren’t something behind it.” The other two
participants suggested the reason they were prescribed for as long as they were/are having some
affiliation with their physician receiving money for maintaining a prescription with them.
Participant 2 strongly stated, “I never once was encouraged to get off the methadone therefore, I
have thoughts on the idea that it may have something to do with money. There was no “harm
reduction” from being on methadone.” There is an idea that physicians may be motivated by
increased benefits for maintaining these medications, whether it be suboxone or methadone.
Participants from each prescription group indicated some form of money motivator within their
interview.
Negative Perspectives. There were also additional negative themes associated with
physician’s worth mentioning. Participants 2, 4, and 5 reported that their physicians never
encouraged them to begin a taper and begin thinking about life outside of MAT. Participant 4
reported persistence on beginning their taper every time they refilled their prescription but
reported receiving a deny after each request. After asking to taper, a reported comment from a
physician said, “if you want to lower your doses, do it on your own.” The lack of encouragement
and direction was “offensive” according to participant 5. Participant 5 indicated their physician
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continually “pushes” them to remain on MAT regardless of their goals. Participant 2 indicated
they only saw their physician twice, which made addressing their treatment difficult. Each
participant indicated negative experiences while working with their physician and their MAT.
Participant-related factors
Positive Choice. Positive perspectives were not included in the physician-related factors
section due to the positives recorded were associated with the client’s ability to have a choice
regarding their treatment. Two participants mentioned that their physician met them where they
were at with their treatment. Participant 1 and 3 provided positive regards towards their
physicians and how they approached their treatment management. Both implied their physicians
were very supportive in their recovery and were meeting them where they are in their recovery.
Participant 1 reported that their physician provided them with information regarding
approximately how long they would be on their prescription. Whereas participant 3 reported their
physician allowed continued treatment for as long as they needed to, to avoid relapsing. They
both participant 1 and 3 reported that their physicians are there to help them through their
recovery on their own terms. However, the concluding factor for both participants was that their
treatment and length are solely up to them.
Negative Choice. Two participants explained that they are partly held responsible for the
continuation of their MAT. Interestingly, they both noted the withdrawals as a driving motivator
for them to continue treatment. Similar to the thoughts of participant 4, both participants reported
remaining on MAT due to withdrawals being significantly worse than the drug of choice (DOC).
Both mentioned they were “scared” to begin a taper and discontinue due to experiences they
previously encountered with withdrawals. Aside from being afraid of withdrawal experiences,
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one participant stated they remained in treatment initially because they wanted to and enjoyed
the euphoria associated with increasing doses and no desire to change. “I lied because I wanted
more. They asked me if I was experiencing any withdrawal symptoms and I would say yes. I was
never denied any dose increases.”
Table 4
Participant View: Who’s Responsible for Length of Treatment
Responsible

Suboxone (n=4)

Methadone (n=1)

Total (n=5)

Physician

25%

0%

20%

Participant

50%

0%

40%

Both Parties

25%

100%

40%

100%

100%

100%

Total

Table 4 provides a percentage-based visualization regarding the belief of participants for
who were most in control of their length of treatment. Although not directly stated in the
interview, two participants made separate comments concerning a contradiction leading to an
understanding that both parties were in control of the continued treatment. The participant
prescribed suboxone noted that initially the physician was to hold them accountable due to
continuously pushing them to remain on the prescription. However, they are afraid to discontinue
their prescription due to the severity of withdrawals. This participant made known that the
beginning of their treatment was dependent on the physician’s responsibility, resulting in them
being in control due to a fear of withdrawals. This statement placed the participant in a category
of both physician and participant responsible for the length of treatment. For the methadone
participant, it was mentioned that upon initial months of treatment; they would like to have their
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doses increased due to the enjoyment of remaining under the influence. Nevertheless, they stated
the physician was motivated by money to maintain a prescription without physically speaking
with the client. The money motivator was indicated as the prescription continued and the
addiction became increasingly worse. This participant developed an understanding of the
beginning of their treatment was in their control. However, as treatment continued and their
addiction got worse, the perspective regarding who was responsible for their treatment changed
roles. These comments placed both participants in a Both Parties category due to contradictory
truths amongst the two. To conclude, it is essential to understand how parties are responsible for
their prescription.
Opinions and Recommendations
Despite the discussion about who is primarily in control, participants provided
information regarding opinions and recommendations for time spent on medicated assisted
therapy for opioid use disorder. This section will focus on participant treatment
recommendations pertaining to the length of treatment and additional themes found throughout
the data.
Opinions of Methadone. Due to only one participant being prescribed methadone, those
prescribed suboxone were asked to provide any thoughts on the alternative treatment. Of the
four, three mentioned that those prescribed it may receive euphoric highs while being prescribed.
Interestingly noted, participant 4 commented on the euphoric highs attributed to prescription:
I don’t understand why they think it’s effective or why it’s necessary. There are better
ways to go about things. Harm reduction… I understand that, but then why do they have
to bring people up so high, to bring them back down? It doesn’t make sense.
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This participant commented on the full agonistic effects of methadone. Due to there being no
ceiling effect, unlike suboxone, there is a much higher likelihood of experiencing complete
sedation. The participant who was prescribed methadone indicated if having known the effects of
methadone, they would have never begun treatment. Primarily due to the completed sedated life,
they were living with methadone maintenance. This participant reports undergoing an “awful
experience” with their prescription of methadone. The participants prescribed and not prescribed
provided the researcher with negative feedback regarding methadone treatment.
Opinions of Suboxone. All four participants prescribed suboxone provided positive
feedback regarding their experiences with their treatment. Each stated they were thankful for the
opportunity to regain control of their life. However, the two participants prescribed over four
years ended with negative comments. Positive feedback is as followed. Participant 3 states, “I
don’t know if I would have stopped using (illicitly) honestly, and then I got on (suboxone) and
was able to stop.” Each participant stated they were thankful for the opportunity and how far
they have come with their recovery with the help of suboxone. Participant 1 reported suboxone
was a “lifesaver” and believes it has helped them immensely. Other participants concluded it
provides mental clarity with providing the ability to set future goals for themselves. These two
participants' negative comments were related to the length of their prescription. Both participants
reported wishing they would have begun their taper faster than continuing their prescription.
Participants provided research with positive notions regarding suboxone, with conflicts between
participants on how long they should be prescribed.
Recommended Time Length for MAT. Methadone and buprenorphine obtain different
mechanisms of action and intensities of sedation level, so it is necessary to keep
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recommendations for each medication separate. The participants prescribed methadone for two
years and reports to those prescribed not to exceed a year on methadone with a maximum dose of
60mg. This being explained by not allowing oneself to become sedated by the medication and
avoid replacing their previous addiction with the new addiction of methadone. Additionally, this
allocated time frame and the maximum dose may aid with the balance of not becoming sedated
and managing the withdrawals for a short amount of time to taper off the medication eventually.
For the participants prescribed suboxone, there were different beliefs amongst the four
participants. Two indicated that depending on where the person is at with their recovery, to
recommend remaining on MAT for as long as necessary. This will ensure the high-risk person
does not relapse leading to a higher risk of overdosing. Participant 3 states, “if you’re going to
relapse and go back to using, I think you should probably just stay on it.” Of those two, the other
participant mentioned only to be prescribed the medication for roughly a year and a half. The
following two participants mentioned that people prescribed suboxone should get off as soon as
possible. Indicating that once stability is achieved, one should discontinue their prescription.
Participant 4 indicated that six months is “more than enough” for time allowed to get stable and
lessen the chances of intense withdrawals following the taper. They believe the taper should
begin at month three or four, resulting in an approximately six months of medicated treatment.
Participant 5 estimated one to two years but again suggested getting off as soon as possible. This
person reported blaming themselves for continuing treatment as long as they did and wished they
would have been off in a year but felt pressured due to their physician continually doubting their
recovery, as stated. Both participants strongly recommend tapering off MAT before the
withdrawals get severe to where the person is afraid to come off. To conclude, from the reported
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information, it was found that if one is able to abstain from using, to get off MAT as soon as
possible.
For those who are currently prescribed MAT they were asked whether they view
themselves beginning taper in the near future. Participant 5 mentioned in their interview that
their physician denied their request for taper and was told to if they wish to taper, to begin on
their own. The participant reported it was difficult for themselves to have a continued
prescription at the same dose and not a tapered one, to begin to taper themselves. They indicated
hopefully being able to begin a taper on their own soon. Participant 3, on the other hand,
indicated they would continue their prescription due to their physician allowing them to request
changes in their doses whenever they deem necessary. This participant reports requesting to
lower on their own terms and increasing if they feel the low dose is not therapeutic. This
information is important when considering their length of treatment and who is in primary
control. Participant 3 continues with the notion that they are in control, whereas Participant 5
finds it difficult to discontinue the help of their physician to initiate the taper for them upon each
request.
Table 5
Participant Recommended Time Length
MAT (n=5)

< 1 Year

1 - 2 Years

As Needed

Total %

Methadone (n=1)

0

1

0

20%

Suboxone (n=4)

1

1

2

80%

Total

20%

40%

40%

100%
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Table 5 demonstrates the amount of time each participant recommended as necessary for
time spent on medicated assisted treatment. As mentioned above, participants hold different
beliefs regarding the length of treatment. Sixty percent of the participants believe one should be
maintained on medications for a certain amount of time, in contrast, following 40% believe one
should stay on for as long as they need to, depending on where they are at in their recovery.
Those who believe in a certain time period is due to the hardship associated with increased
withdrawal severity and decreased developed dependence from the illicit forms. The two who
believe in extended treatment report that the longer the treatment, the chances of relapsing
decrease.
Psychoeducation. Participants were asked whether they received any counseling services
or co-occurring education for opioid use disorder while receiving their medicated treatment. As
noted in Table 2, only two participants received counseling for their addiction. One mentioned
that while receiving their MAT, their counselor did not address their addiction and only spoke of
minor occurrences within their life. They did not find those services beneficial to their addiction
and were only recommended taper when the participant mentioned one. The other participant,
included attending outpatient services while receiving MAT to strengthen their understanding of
triggers and develop a relapse prevention plan. This participant reports positive experiences with
both medication and counseling integrated with their recovery to battle their addiction.
The other three participants report never attending counseling services for opioid use
disorder while being prescribed MAT. However, they each reported that counseling should be
encouraged while receiving any opioid treatment medication. “This is how people could quit and
be successful” quoted from participant 5. Healthy coping skills are needed to be developed to
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build accountability and learn to work through addiction. Participant 4 stressed setting a new
path for themselves (clients prescribed) and actually living a sober life, not just being sober, e.g.,
learning differently and forming new habits. Counseling services for those who struggle with
mental health attributed to use were noted can be beneficial to tackle addiction. Individual and/or
outpatient counseling services were predominant when asking participants about their thoughts
regarding psychoeducation for opioid use disorder.
Summary
A conclusion from the small sample of participants, it was found approximately equal
responsibility of both the participant and physician regarding the time spent on medications for
opioid use disorder. Two participants addressed that the length of their treatment was utterly
dependent on their recovery stage. In contrast, another two believed the physician was strictly
maintaining their prescription for monetary benefit with no regard to harm reduction. The fifth
participant is what determined an equal balance between both contradicting sides. This
participant believed they were in control due to the fear of withdrawals yet believes the physician
has some monetary grounding force for the continuation of the prescription. Due to the sides
obtaining equal beliefs, additional comparisons were noted to draw a further summary of the
data.
With a focus on who was in control, after thorough analyzing and comparing tables, a
correlation was noticed between those with over ten years of addiction and ages over 30 (n=3),
held negative perspectives that it was the physician’s responsibility for the amount of time they
maintained the prescription. These same participants agreed on their ideal time of prescribed
medicated treatment to be roughly one year. On the other hand, those with active addiction less
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than ten years (n=2), stated it is solely up to them regarding how long they maintain their
medication for recovery. The two groups of same participants were noticed to obtain similar
characteristics of similar lengths in addiction and belief regarding role in continued treatment.
Along with lengths of addiction, it was discovered that those in the same group of more
prolonged addiction held more negative perspectives towards their physicians than those two
were in the less than ten years of addiction group. Those participants reported positive feedback
regarding their physician and how they approached their treatment prescription.
In addition to years of addiction, it was noticed that the participants prescribed in the year
2012 (n=2), received over the recommended doses of MAT for their specific prescription. As
mentioned in Chapter II regarding physician’s lack of education, those doses may have exceeded
the recommended dose due to the lack of education. A correlation between the small sample of
those two participants with their beliefs to who was responsible for the length of the treatment
was anecdotally documented. Since methadone was synthesized in 1965 and suboxone in 2006,
the amount of research across both medications varies. The participant prescribed in 2012
worked with a doctor who had a maximum of six years of knowledge about the medication. This
raises a concern about whether they were educated enough on the medication protocol for
prescribing. Conversely, those who received MAT of suboxone at later dates (2018 to present),
have a higher likelihood of obtaining a physician who is more educated on the medications and
how to prescribe. These participants were noticed to receive appropriate doses for their
treatment, in addition to holding the belief that they were either in control – or partly in control
(Participant 5) for their prescription being continued. This participant began treatment in 2016,
whereas the other two were at a much later date.
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Due to the small sample size, a relationship was found between the length of MAT and
who was accountable for treatment with the suboxone participants (n=4). The methadone
participant is not included in this relationship due to being the only participant recruited in the
study. The participants who were maintained for four to five years stated it was their physician
who was responsible. The other two participants, less than three years, believe they are in
control. Along with this information, gender was noted to be affiliated with this relationship. The
two participants who believed they were not in control of their time spent on MAT were males,
and the two less than three years were females. To conclude, the participants with shorter MAT
prescriptions stated they who were in control, whereas the one with a longer MAT prescription
believes it was not.
Switching focus to those who received counseling services and was held accountable,
there was no correlation. Only two members received services with one believing each was held
accountable. The other three participants had similar findings. To conclude, there was no
relationship between those receiving counseling services for OUD who believed it was their
responsibility or their physicians. To establish a relationship between these two factors, more
data between belief and counseling would be necessary.
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Chapter V: Discussion
Hypothesis
This research focuses on the factors of whom clients believe is responsible and in control
of their treatment regimen for how long they maintain MAT prescription regarding their opioid
use disorder. Due to the small sample size, the findings were not strong enough to produce a
concrete conclusion. Questions developed as the researcher developed the hypothesis leading to
future research topics and focus. First, it will discuss the length of addiction, followed by the
developed hypothesis. A researcher's perspective is provided in addition to the study's
limitations.
From a philosophical perspective, after concluding the results and understanding the
characteristics of those who have maintained addiction for a long time, blaming and justifying
are common factors for those who have struggled with addiction. These cognitive distortions are
central thoughts to those affected. With that in mind, one can believe that those who obtained the
more prolonged addiction may still obtain those negative thought patterns if they abided by them
and have used them as a bias towards their physician. It is not intended to direct the conclusions
of why those who believe the physician is responsible, but it was noteworthy that may include
distorted thinking in some responses. Are these participants still affected by those negative
thought processes? However, it will identify that this statement will not affect the discussion and
conclusion.
Despite the multiple unanswered questions this study has developed, this study's
concluding hypothesis is presented. The longer a person is prescribed MAT, the harder it is for
them to taper off the medication and become non-dependent on opioids/opiates. While the study
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included questions to the participants regarding psychoeducation and therapy services, it is
highly encouraged to engage in therapy to help decrease the amount of time spent on medicated
assisted therapy. This hypothesis was derived from all parts of the study dependent on harm
reduction, length of treatment, and counseling services.
Focusing on the concept of harm reduction may play a role in why some may need
extended MAT due to the severity of their addiction and withdrawal symptoms. A question
raised in this area was, are physicians causing more harm to the client by not engaging in a
taper? This then causes an increase in withdrawals if discontinued. It is thought that the longer
the person is prescribed, harm reduction decreases for the client due to the increase in severity in
experienced withdrawals upon completion of the medication. Two participants stated they are
afraid to begin their taper and eventually discontinue their prescription due to the anxiety
developed from a fear of experiencing withdrawals. Those same participants who did taper off
medications stated in their interview, it was the worst experience for six weeks to six months,
worse than what they had experienced previously from their initial drug of choice. Shortening
their time spent on MAT may decrease their eventual withdrawals from discontinuation. It is
thought, if a person actively attends co-occurring education for their addiction, they may develop
an understanding of why physicians integrate this approach into their treatment. People typically
do not want to be prescribed and tied to medication for the rest of their life. Educating people
prescribed these medications should decrease the amount of time spent on MAT and allow for a
non-medicated dependent life.
Psychotherapy is currently encouraged to clients prescribed MAT; however, it is not
required. Concerns to lessen the time spent on MAT should require those prescribed to receive
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counseling services simultaneously. As stated by the participants, counseling is suggested to
build a new foundation to live by, such as healthier coping skills and relapse prevention.
Psychotherapy required with MAT would increase the person's resiliency to avoid relapse,
understand triggers, and develop coping skills to build a structured life without use. MAT would
help those at the beginning of recovery manage the deathly withdrawals while learning the new
skills concurrently. Psychotherapy and MAT used together could decrease the amount of time
spent in treatment altogether.
As briefly mentioned, withdrawals are a concern for those prescribed MAT and whether
to continue their prescription or "bite the bullet" and manage through them to become free from
the ball and chain effect stated in Chapter II. This generated another question, should counseling
services be required with a low dose MAT prescription followed by marked stability?
Considering this question, maintaining a low-dose prescription may allow the client to remain
stable, hoping to decrease the severity associated with the final step of discontinuing the
medication.
A difficulty is noting whether the client is truly sedated and experiencing withdrawal
when physicians administer the Clinical Opiate Withdrawal Scale (COWS) as mentioned in
Chapter II, or whether they are lying. Clients may lie about withdrawal symptoms to increase
their prescribed dose. This was seen in the participants prescribed methadone. They stated that at
the beginning of their treatment; they lied to increase their dose. However, the physician did not
question or further analyze whether the severity was as reported. Not further assessing could be
associated with the lack of education previous studies implied regarding physicians’ knowledge.
As the medical field grows, it is hoped that it can develop a way to detect lying and false
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information provided on the COWS to avoid increasing their dose when unnecessary. These
lower doses may also make it easier for the client to decrease their time spent on prescribed
treatment and decrease withdrawals' severity. Finally, the more educated the physician is on
MAT, the more helpful they may be prescribing the medications, allowing for more direction on
individualized treatment plans and educating the client.
Conclusion
From a researcher's perspective, both participants and physicians are held accountable for
continued medicated treatment therapy. If the physicians use MAT as a form of harm reduction,
the client may challenge the physician by asking for a taper at a point in their treatment. Instead,
the physician may disapprove of their request due to them not believing they are ready to
discontinue and remain abstinent. The physician is thought to have the best interest in the client.
However, what happens when the length exceeds and the client is ready, but the physician does
not allow for it? This question was noticed in two participants who volunteered to be a part of
this study. One of the participant’s physicians lost their license and resulted in them having to
begin their taper themselves. The second participant had to challenge their physician by asking
for a taper, leading them to begin tapering themselves. The hopes of this situation remain that
they take their recovery into their own hands, allowing themselves to taper themselves and
eventually discontinue their prescription correctly.
With an emphasis on the physician, they have increased responsibility for the continued
prescription over the time clients are prescribed. Regarding client thoughts, why would
withdrawals be more severe from those on MAT than those discontinuing drugs such as heroin
or fentanyl? Is this due to the purity levels associated with methadone? However, suboxone
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cannot be attributed to that conclusion due to the ceiling effect it obtains. Due to it being an
antagonist, it makes it harder for a user to abuse the drug. It still is questioned why would
withdrawals associated with suboxone be increasingly worse then? It is thought to be attributed
to a monetary value to replace an illicit drug with a prescription that will guarantee paid
fulfillment through insurance. If a physician were to use the notion of harm reduction for the
approach, it would make sense to provide the education as explained earlier to decrease their risk
levels of relapse and continued use. Ethical dilemmas are flagged where beneficence and nonmaleficence are concerned. Beneficence being an oath that the physician does good for their
clients and non-maleficence may then be concerned to where the physician takes an additional
oath to do no harm. Indeed, physicians may have good intentions, but may break these oaths
when making the wrong decision and not providing therapeutic services. Lastly, over the years,
the number of waivers has increased for physicians to maintain clients. It can view this from two
perspectives. Again, one is a monetary increase for the physician and two for an increase in
helping those diagnosed with an opioid use disorder. Whichever lens one wants to look through,
the ending conclusion would hope to be focused on eventually discontinuing their prescription to
help clients live a non-medicated dependent life.
To provide appropriate services and follow guidelines mentioned in Chapter II,
physicians should consider administering the COWS screening tool to evaluate the client for
stability and ensure they are not abusing their prescription. Treatment goals should also be
heavily considered upon initial assessment to determine which approach is appropriate for them
individually. Deciding whether harm reduction or abstinence is the long-term goal will allow the
physician to meet the client where they are at and provide effective therapeutic services. The
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clinician should also maintain self-education on the MAT they are prescribing to ensure they are
up to date on the most effective way to treat those with this detrimental substance use disorder.
Although the responsibility of remaining on medication for opioid use disorder is amongst
both physician and client, it can be concluded it is solely up to the client whether or not they stay
on the medication or not. However, if the client wishes to discontinue treatment, they may, have
an increased risk of relapse and withdrawals. They may also taper themselves off the prescription
they receive and avoid those side effects without the help of their physician and not continue a
life tied to a medication. Contrarily, the client may also choose to continue their treatment due to
the security of having a continuous prescription of opiate medications to fuel their addiction
without the risk of overdosing and an increase in purity of the drug. The client may view this as a
benefit to maintaining their addiction with the low cost of obtaining the medication. They also
have the security of knowing they may never have to experience withdrawals due to the
continued prescription. Unlike when using street drugs, they have to go through the struggle of
having enough money to obtain it, along with finding a dealer who has some at the time of need.
Clients are not court-ordered to maintain prescription, so remaining on the prescription is the
bottom line in their hands. They have the right to choose to continue or discontinue their
prescription.
To conclude the research discoveries and thoughts pertaining, there was not enough
participant data to develop a clear understanding of who may be held accountable when clients
are prescribed MAT for OUD. It is thought that with proper education and counseling while
prescribed the medications, one may have greater chances of decreasing the time spent on
medicated assisted therapy and live a life independent from opioids. Decreasing time and being
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on medications will help the client achieve their goal of complete abstinence, and for those who
believe their recovery does not fully begin once they are off MAT.
Limitations
The limitations of this study are as follows. The study consists of using a limited number
of five participants, with only one methadone perspective. Since this is a qualitative study,
acquiring data from many of the opioid use population would require an intense amount of time
and research. The small number of participants contain different demographics – specific opioid
choice in their addiction, treatment methods they acquired, length of initial addiction, treatment
duration, and whether they received counseling. Furthermore, participants may withhold
information due to personal reasons that may affect data. Lastly, it is essential to note that some
participants have a personal relationship with the researcher, which may influence data.
However, researcher bias is taken heavily into consideration to avoid alterations of results and
conclusions. This study also only included participants from a Caucasian ethnicity and did not
include participants from different cultures.
Participants with different characteristics hold limitations by obtaining different
perceptions and viewpoints of substance use and abuse. With a small number of participants, the
opportunity of obtaining more data to derive a concrete conclusion limits the findings. Each
participant received their drug of choice, limiting the study by the treatment methods to one
specific opioid. Meaning one participant may use heroin as their illicit choice and methadone as
their treatment method. In contrast, another could use oxycodone for their addiction and
buprenorphine as their treatment.
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Along with the different illicit and treatment choices, participants differ from the
addiction and the duration of treatment methods. One participant may come from a history of
substance abuse for ten years, whereas another only a single year. The course of addiction limits
the findings for the treatment method's tapering effect and length of treatment. Since one
participant may show long-term addiction over another, this could determine the success of the
treatment. Along with the duration of the habit, the course of treatment has significance for a
limitation. A participant's success rate could be different from others due to their treatment
length, relying on physical dependence. Those who have completed treatment in the previous
year might offer different experiences and opinions than those who are currently prescribed, in
addition to those who have been prescribed for more extended periods of time.
Results may be affected due to the years the participants were prescribed MAT.
Participants may have different opinions regarding their treatment due to obtaining a physician
with possibly less education on prescribing MAT compared to those currently prescribed.
Current physicians may obtain greater knowledge regarding the effects, proper dosing, and
treatment protocol compared to those prescribing the medications when there was not much
information about adequate services.
Lastly, participants are encouraged to disclose information regarding their addiction and
treatment, including their feelings, experiences, and other information. What limits this specifier
is that participants can withhold some variables from the interviewer based on personal reasons.
Reasonings may include fear of judgment and legal concerns associated with their addiction.
Traumatic experiences may not be discussed with flashbacks of their use and treatment, causing
a relapse trigger.
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In addition to the participant's limitations, this study also lacks current prescribers'
thoughts and experiences. This limitation may cause a bias against prescribers due to only
information data from the receiving parties. This limitation is acknowledged when conducting
research being the bias concern associated with that piece of information. Research from
previous studies regarding physicians' experiences has provided an analysis with enough
information to gather a general notion of their knowledge. Furthermore, the years the participants
were prescribed can alter the opinions regarding the treatment. Those prescribed when suboxone
first received FDA approval may have received a less educated physician than those who have
received a physician later, who have more education and understanding of the risks, benefits, and
how to administer the medications properly.
Admittingly, this study has various limitations; the data provided is a steppingstone for
future research. The study developed numerous questions for the researcher to continue
exploration within this field of study. The treatment of opioid use disorder develops serious
questions about medications, treatment length, physician's role, the client's role, and approaching
this severe crisis the world is facing. As the medical field continues developing alternative
understandings of mental health alongside addiction, physicians, doctors, therapists, and
psychologists can mend together different approaches to create effective services for those most
affected.
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